Methods for treatment of severe acute respiratory syndrome...

Details Methods for treatment of severe acute respiratory syndrome... Methods for treatment of severe acute respiratory syndrome...

2011-02-22

2011-02-22

Nickol, Gary B. (Department: 1647)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S145100, C435S335000

Reexamination Certificate

active

07892563

ABSTRACT:
Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.

REFERENCES:
patent: 4376110 (1983-03-01), David et al.
patent: 4699880 (1987-10-01), Goldstein
patent: 5096906 (1992-03-01), Mandell et al.
patent: 5118500 (1992-06-01), Hänel et al.
patent: 5196430 (1993-03-01), Mandell et al.
patent: 5395760 (1995-03-01), Smith et al.
patent: 5508300 (1996-04-01), Duplantier
patent: 5547979 (1996-08-01), Christensen, IV et al.
patent: 5563143 (1996-10-01), Cohan et al.
patent: 5594106 (1997-01-01), Black et al.
patent: 5596013 (1997-01-01), Duplantier
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5635350 (1997-06-01), Eberle et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 5691382 (1997-11-01), Crimmin et al.
patent: 5747514 (1998-05-01), Beckett et al.
patent: 5795859 (1998-08-01), Rathjen et al.
patent: 5821262 (1998-10-01), Crimmin et al.
patent: 5824519 (1998-10-01), Norris et al.
patent: 5834485 (1998-11-01), Dyke et al.
patent: 5861510 (1999-01-01), Piscopio et al.
patent: 5863949 (1999-01-01), Robinson et al.
patent: 5872146 (1999-02-01), Baxter et al.
patent: 5883131 (1999-03-01), Burgess et al.
patent: 6036978 (2000-03-01), Gombotz et al.
patent: RE36755 (2000-06-01), Smith et al.
patent: 6080580 (2000-06-01), Baker et al.
patent: 6083534 (2000-07-01), Wallach et al.
patent: 6107273 (2000-08-01), Jameson et al.
patent: 6114517 (2000-09-01), Monia et al.
patent: 6277969 (2001-08-01), Le et al.
patent: 6419934 (2002-07-01), Tobinick
patent: 2001/0021380 (2001-09-01), Pluenneke
patent: 0 125 023 (1984-11-01), None
patent: 0 171 496 (1986-02-01), None
patent: 0 173 494 (1986-03-01), None
patent: 0 184 187 (1986-06-01), None
patent: 0 212 489 (1987-03-01), None
patent: 0 218 868 (1987-04-01), None
patent: 0 288 088 (1988-10-01), None
patent: 0 308 378 (1989-03-01), None
patent: 0 398 327 (1990-11-01), None
patent: 0 412 486 (1991-02-01), None
patent: 0 433 900 (1991-06-01), None
patent: 0 492 448 (1992-07-01), None
patent: 0 526 905 (1993-02-01), None
patent: 0 516 785 (1996-02-01), None
patent: 2 291 422 (1996-01-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 86/02269 (1986-04-01), None
patent: WO 88/04300 (1988-06-01), None
patent: WO 88/09810 (1988-12-01), None
patent: WO 90/11364 (1990-10-01), None
patent: WO 91/02078 (1991-02-01), None
patent: WO 92/07076 (1992-04-01), None
patent: WO 92/13095 (1992-08-01), None
patent: WO 96/00215 (1996-01-01), None
patent: WO 96/01825 (1996-01-01), None
patent: WO 98/17281 (1998-04-01), None
patent: WO 98/30213 (1998-07-01), None
patent: WO 98/50347 (1998-11-01), None
patent: WO 98/54366 (1998-12-01), None
patent: WO 99/04001 (1999-01-01), None
patent: WO 99/15524 (1999-04-01), None
patent: WO 99/18095 (1999-04-01), None
patent: WO 99/49830 (1999-10-01), None
patent: WO 99/56764 (1999-11-01), None
patent: WO 99/66936 (1999-12-01), None
patent: WO 00/09150 (2000-02-01), None
patent: WO 01/30360 (2001-05-01), None
Zhang et al (Infection and Immunity 72:4410-4415, Aug. 2004) (abstract only cited).
Wong et al (Clinical and Experimental Immunology 136:95-103, Apr. 2004) (abstract only cited).
Ng et al (Pediatrics 113:pe7-14, Jan. 2004).
Wang et al (Chinese journal of tuberculosis and respiratory disease, 26:586-589, Oct. 2003) (abstract only cited).
Ward et al (Antiviral Therapy 10:263-75, 2005) (abstract only cited).
So et al (Lancet, 361:1615-1617, May 10, 2003).
Palladino et al (Nature Reviews Drug Discovery 2:736-746, Sep. 2003).
Nicholls et al (Lancet 361: 1773-1778, published online May 16, 2003).
Cheung et al, Induction of proinflammatory cytokines in human macrophages by Influenza A (H5N1)viruses; a mechanism for the unusual severity of human disease?, Lancet, 360, 1831-1837, 2002.
Nicholls et al, Lung Pathology of fatal severe acute respiratory syndrome, Lancet, 361, 1773-1778, 2003; published on line on May 16, 2003.
Hooper et al., Alterations in TNF-alpha receptor signaling in Experimental Coronavirus Retinopathy, Invest Ophtamol Vis Sci, 45, Suppl., Meeting abstract 565-B538, 2004.
Tobinick E, TNF-alpha Inhibition for potential therapeutic modulation of SARS Coronavirus infection, Curr. Med. Res. Opin., 20, 39-40, 2004.
Update: Severe Acute Respiratory Syndrome—United States, 2003, M.M.W.R., 52(17):388-90 (May 2, 2003).
Preliminary Clinical Description of Severe Acute Respiratory Syndrome, M.M.W.R., 52(12):255-256 (Mar. 28, 2003).
Poutanen et al.,New England Journal of Medicine, Mar. 31, 2003, LOW-1-LOW11, www.nejm.org.
Rota, P.A., et al., Research Articles, Character of Novel Coronavirus Associated with Severe Acute Respiratory Syndrome, May 30, 2003, vol. 300, Science, www.sciencemag.org, pp. 1394-1399.
Marra, M.A., et al., The Genome Sequence of the SARS-Associated Coronavirus, May 30, 2003, vol. 300, Science, www.sciencemag.org, pp. 1399-1404.
D. Cyranoski, Critics slam treatment for SARS as ineffective and perhaps dangerous,Nature, 423:4, May 1, 2003, p. 4.
Nesmith, Sars Vaccine Will Take “Several Years,” Congress Told,New York Times Syndicate; Apr. 7, 2003, May 21, 2003, (http://www.nlm.nih.gov/medlineplus/print
ews/fullstory—12280.html), pp. 1-2.
Smith et al., The Active Form of Tumor Necrosis Factor Is a Trimer,J. Biol. Chem. vol. 262:6951-6954, May 25, 1987.
M. Krigler et al., A Novel Form of TNF/Cachectin Is a Cell Surface Cytotoxic Transmembrane Protein: Ramifications for the Complex Physiology of TNF, Cell, vol. 53, pp. 45-53, Apr. 8, 1988.
Beutler et al., Cachectin and tumor necrosis factor as two sides of the same biological coin,Nature, vol. 320, pp. 584-588 Apr. 17, 1986.
Old, Tumor Necrosis Factor (TNF), Science, vol. 230, pp. 630-632.
Le et al., Tumor Necrosis Factor and Interleukin 1: Cytokines with Multiple Overlapping Biological Activities, Laboratory Investigation, vol. 56, No. 3, pp. 234-248, 1987.
Rubin et al., Nonhematopoietic Cells Selected For Resistance To Tumor Necrosis Factor Produce Tumor Necrosis Factor, J. Exp. Med., vol. 164, Oct. 1986, pp. 1350-1355.
Spriggs et al., Induction of tumor necrosis factor expression and resistance in a human breast tumor cell line, Proc. Natl. Acad. Sci., vol. 84, pp. 6563-6566, Sep. 1987.
Cuturi et al., Independent Regulation Of Tumor Necrosis Factor And Lymphotoxin Production By Human Peripheral Blood Lymphocytes, J. Exp. Med., vol. 165, Jun. 1987, pp. 1581-1594.
Sung et al., Production of tumor necrosis factor/cachectin by human B cell lines and tonsillar B cells, J. Exp. Med., vol. 168, Nov. 1988, pp. 1539-1551.
Pober et al., Tow distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells1, The Journal of Immunology, vol. 136, No. 5, Mar. 1, 1986, pp. 1680-1687.
Pober et al., Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin 1 species1, The Journal of Immunology, vol. 168, No. 10, pp. 3319-3324, May 15, 1987.
Camussi et al., Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor, J. Exp. Med., vol. 166, Nov. 1987, pp. 1390-1404.
Cerami et al., The role of cachectin/TNF in endotoxic shock and cachexia, Ommunology Today, vol. 9, No. 1, 1988, pp. 28-31.
Oliff et al., Tumors secreting human TNF/Cachectin induce cachexia in mice, Cell, vol. 50, pp. 555-563, Aug. 14, 1987.
Piguet et al., Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs-host disease, J. Exp. Med., vol. 166, Nov. 1987, pp. 1280-1289.
Michie et al., Tumor necrosis factor

Affiliated with

Also associated with

Rating

Methods for treatment of severe acute respiratory syndrome... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for treatment of severe acute respiratory syndrome..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment of severe acute respiratory syndrome... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2628640